CATX - Perspective Therapeutics, Inc.

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).

Oct 08, 2026 02:16 AM • globenewswire.com

Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterated by BTIG Research in a research note issued on Wednesday, Benzinga reports. They currently have a $14.00 price objective on the stock. BTIG Research's target price would suggest a potential upside of 474.95% from the company's current price. Several other equities research

Oct 07, 2026 04:07 AM • defenseworld.net

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's [²¹²Pb]VMT-α-NET program have been accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium taking place November 5 to 7, 2026, in Las Vegas, Nevada.

Oct 07, 2026 02:16 AM • globenewswire.com

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company.

Oct 06, 2026 10:45 PM • defenseworld.net

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.

Oct 02, 2026 07:46 AM • globenewswire.com

This $3 Biotech Could Be Worth $11.45, Analyst Says

Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical cancer treatments, according to William Blair.

Sep 18, 2026 09:52 AM • benzinga.com

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

Sep 14, 2026 02:16 AM • globenewswire.com

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain.

Sep 11, 2026 02:00 AM • globenewswire.com

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain. The conference plans to release further details for abstracts on November 4, 2026.

Sep 11, 2026 02:00 AM • globenewswire.com

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for SSTR2-expressing NETs shows sustained efficacy and safety, with pivotal Phase 3 initiation targeted for late 2026. Upcoming data readouts for both NET and MC1R-positive melanoma programs, including ESMO 2026 and OPDIVO combination updates, present significant value inflection points.

Sep 01, 2026 02:23 PM • seekingalpha.com

Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 450,097 shares of the company's stock after buying an additional 358,540 shares during the quarter. Dimensional Fund Advisors

Aug 13, 2026 11:37 PM • defenseworld.net

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Aug 04, 2026 06:41 AM • zacks.com

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Aug 03, 2026 07:35 AM • zacks.com

Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP

Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,049,999 shares of the company's stock after purchasing an additional 2,839,266 shares during the quarter.

Jul 31, 2026 11:44 PM • defenseworld.net

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Jul 31, 2026 02:30 AM • globenewswire.com

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Jul 29, 2026 06:56 AM • zacks.com

Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 926,557 shares of the company's stock, valued at approximately $3,864,000. Perspective Therapeutics comprises 3.1% of Ally

Jul 28, 2026 11:45 PM • defenseworld.net

ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 687.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 749,335 shares of the company's stock after buying an additional 654,142 shares

Jul 28, 2026 11:45 PM • defenseworld.net

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the European Commission (EC) has granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

Jul 28, 2026 02:30 AM • globenewswire.com

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.

Jul 17, 2026 08:22 AM • globenewswire.com

Perspective Therapeutics initiated with an Outperform at BMO Capital

$11.00 (was $3.21)

BMO Capital

Aug 18, 2026 04:21 PM • TheFly

Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)

$12.00 (was $5.09)

Greg Renza · Truist Financial

Mar 17, 2026 08:35 AM • StreetInsider

Perspective Therapeutics initiated with an Overweight at Piper Sandler

$16.00 (was $5.03)

Biren Amin · Piper Sandler

Feb 19, 2026 05:11 AM • TheFly

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

$12.00 (was $4.26)

H.C. Wainwright

Jan 30, 2026 06:08 AM • TheFly

Perspective Therapeutics price target lowered to $7 from $18 at UBS

$7.00 (was $2.12)

David Lai · UBS

Nov 20, 2025 07:26 PM • TheFly

Perspective Therapeutics initiated with a Buy at BTIG

$14.00 (was $4.20)

Jeet Mukherjee · BTIG

Oct 10, 2025 06:59 AM • TheFly

UBS Starts Perspective Therapeutics Inc (CATX) at Buy

$20.00 (was $11.69)

David Dai · UBS

Oct 23, 2024 11:50 PM • StreetInsider

Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

$22.00 (was $12.66)

Jeff Jones · Oppenheimer

Oct 14, 2024 02:07 AM • StreetInsider

Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy

$21.00 (was $12.28)

Nicole Germino · Truist Financial

Sep 25, 2024 02:10 AM • StreetInsider

Perspective Therapeutics initiated with a Buy at BofA

$24.00 (was $12.82)

Alec Stranahan · Bank of America Securities

Jul 25, 2024 02:11 AM • TheFly

Perspective Therapeutics Inc (CATX) PT Raised to $19 at Oppenheimer

$19.00 (was $11.93)

Jeff Jones · Oppenheimer

Jun 18, 2024 03:26 AM • StreetInsider

RBC Capital Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

$3.00 (was $1.15)

Gregory Renza · RBC Capital

Jun 14, 2024 02:20 AM • StreetInsider

Perspective Therapeutics Inc (CATX) PT Raised to $2 at Oppenheimer

$2.00 (was $1.57)

Jeff Jones · Oppenheimer

May 15, 2024 11:06 AM • StreetInsider